S100B and metabolic disease: The identification of the ADRB3-S100B signaling axis provides a mechanistic framework for understanding SCN-driven BAT regulation and opens new avenues for therapeutic strategies targeting metabolic disorders associated with circadian disruption, such as obesity and insulin resistance.